RESUMO
Neurofibromatosis type II (NF2) is a disease that needs new solutions. Vestibular schwannoma (VS) growth causes progressive hearing loss, and the standard treatment, including surgery and radiotherapy, can further damage the nerve. There is an urgent need to identify an adjunct therapy that, by enhancing the efficacy of radiation, can help lower the radiation dose and preserve hearing. The mechanisms underlying deafness in NF2 are still unclear. One of the major limitations in studying tumor-induced hearing loss is the lack of mouse models that allow hearing testing. Here, we developed a cerebellopontine angle (CPA) schwannoma model that faithfully recapitulates the tumor-induced hearing loss. Using this model, we discovered that cMET blockade by crizotinib (CRZ) enhanced schwannoma radiosensitivity by enhancing DNA damage, and CRZ treatment combined with low-dose radiation was as effective as high-dose radiation. CRZ treatment had no adverse effect on hearing; however, it did not affect tumor-induced hearing loss, presumably because cMET blockade did not change tumor hepatocyte growth factor (HGF) levels. This cMET gene knockdown study independently confirmed the role of the cMET pathway in mediating the effect of CRZ. Furthermore, we evaluated the translational potential of cMET blockade in human schwannomas. We found that human NF2-associated and sporadic VSs showed significantly elevated HGF expression and cMET activation compared with normal nerves, which correlated with tumor growth and cyst formation. Using organoid brain slice culture, cMET blockade inhibited the growth of patient-derived schwannomas. Our findings provide the rationale and necessary data for the clinical translation of combined cMET blockade with radiation therapy in patients with NF2.
Assuntos
Perda Auditiva/etiologia , Neurofibromatose 2/complicações , Neurofibromatose 2/radioterapia , Neuroma Acústico/complicações , Neuroma Acústico/radioterapia , Proteínas Proto-Oncogênicas c-met/metabolismo , Adolescente , Adulto , Animais , Encéfalo/metabolismo , Dano ao DNA , Feminino , Audição , Humanos , Masculino , Camundongos , Pessoa de Meia-Idade , Neurilemoma/complicações , Neurilemoma/radioterapia , Neurofibromina 2/genética , Técnicas de Cultura de Órgãos , Radioterapia , Transdução de Sinais , Adulto JovemRESUMO
(1) Background: This study aimed to evaluate the efficacy and treatment-related toxicity of proton radiotherapy (PRT) for vestibular schwannoma (VS) in patients with neurofibromatosis type 2-related schwannomatosis (NF2). (2) Methods: Consecutive NF2 patients treated with PRT for VS between 2004 and 2016 were retrospectively evaluated, focusing on tumor volume, facial and trigeminal nerve function, hearing, tinnitus, vestibular symptoms, and the need for salvage therapy after PRT. (3) Results: Eight patients were included (median age 36 years, 50% female). Median follow-up was 71 months. Five (63%) patients received fractionated PRT and three (38%) received PRT radiosurgery for VS. Six patients (75%) received prior VS surgery; three also received bevacizumab. Six patients (75%) did not require salvage therapy after PRT. Two patients (25%) with residual hearing lost it after PRT, and six had already lost ipsilateral hearing prior to PRT. Tumor and treatment-related morbidity could be evaluated in six patients. Following PRT, conditions that occurred or worsened were: facial paresis in five (83%), trigeminal hypoesthesia in two (33%), tinnitus in two (33%), and vestibular symptoms in four patients (67%). (4) Conclusion: After PRT for VS, the majority of the NF2 patients in the cohort did not require additional therapy. Tumor and/or treatment-related cranial nerve deficits were common. This is at least partly explained by the use of PRT as a salvage treatment after surgery or bevacizumab, in the majority of cases. There remains the further opportunity to elucidate the efficacy and toxicity of proton radiotherapy as a primary treatment.
Assuntos
Neurofibromatose 2 , Neuroma Acústico , Zumbido , Humanos , Feminino , Adulto , Masculino , Neurofibromatose 2/complicações , Neurofibromatose 2/radioterapia , Neurofibromatose 2/diagnóstico , Neuroma Acústico/radioterapia , Neuroma Acústico/cirurgia , Prótons , Estudos Retrospectivos , Bevacizumab/uso terapêutico , Resultado do Tratamento , SeguimentosRESUMO
BACKGROUND: The use of radiotherapy (RT) for the treatment of vestibulocochlear schwannomas is standard in patients with type 2 neurofibromatosis (NF2). In the general population, fractionated RT (FRT) can achieve good results compared to single-dose radiosurgery (SRS). We aimed to assess whether this is true for NF2 patients as well. METHODS: This retrospective cohort study included 34 patients and 54 lesions treated between 2010 and 2023 in a single university hospital. RESULTS: Thirty-four patient charts were assessed. The median follow-up was 62.6 months (range, 7.1-135.8 months). Lesion size (median larger diameter, 2.5 cm) was correlated with the use of FRT (P > 0.001). Younger age also was correlated with FRT (P = 0.006). Median overall survival and progression-free survival (PFS) were not reached. The overall control rate was 76.5%, and the mean PFS was 49.8 months, compared with . 90.5% and 57.2 months, respectively, for SRS and 66.7% and 44.9 months, respectively, for FRT. There were no differences between the 2 groups in hearing loss, tinnitus, and facial palsy. CONCLUSIONS: In the NF2 population, FRT may yield worse control rates than SRS. Whenever possible, it is preferable to not fractionate treatment for these patients. Nevertheless, the FRT results were still good. More and larger prospective trials are warranted.
Assuntos
Neurofibromatose 2 , Neuroma Acústico , Radiocirurgia , Humanos , Neuroma Acústico/complicações , Neuroma Acústico/radioterapia , Neuroma Acústico/cirurgia , Neurofibromatose 2/complicações , Neurofibromatose 2/radioterapia , Radiocirurgia/métodos , Estudos Retrospectivos , Estudos Prospectivos , Resultado do Tratamento , SeguimentosRESUMO
PURPOSE: Neurofibromatosis type 2 (NF2) is a genetic disorder that is associated with multiple tumors of the nervous system, and approximately one half of patients present with meningiomas. For patients with multifocal disease, somatostatin receptor-targeted peptide receptor radionuclide therapy (PRRT) might be a suitable systemic treatment option. PATIENTS AND METHODS: Between March 2015 and August 2017, 11 NF2 patients (7 females and 4 males; mean age, 39 ± 12 years) with multifocal, progressive meningiomas underwent a median of 4 cycles of PRRT (range, 2-6 cycles). Acute and chronic adverse events were recorded according to National Institutes of Health's Common Toxicity Criteria (CTC) version 5.0. Follow-up MRIs (every 3 to 6 months), using the Response Assessment in Neuro-Oncology response criteria for meningiomas, were used to assess treatment responses. RESULTS: Peptide receptor radionuclide therapy was well tolerated in all patients without any relevant acute adverse effects. Transient hematologic toxicity (CTC grade 3) was observed in 2 subjects. Somatostatin receptor-directed radiopeptide therapy resulted in radiological disease stabilization in 6 of 11 patients. Median progression-free survival was 12 months (range, 1-55 months), and overall survival was 37 months (range, 5-61 months). CONCLUSIONS: Based on our retrospective pilot data, PRRT is feasible and well-tolerated in NF2 patients. It might offer a suitable treatment option in subjects with multiple, recurrent, or treatment-refractory meningiomas.
Assuntos
Neurofibromatose 2/radioterapia , Receptores de Somatostatina/metabolismo , Adulto , Idoso , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neurofibromatose 2/diagnóstico por imagem , Neurofibromatose 2/metabolismo , Octreotida/uso terapêutico , Estudos RetrospectivosRESUMO
Vestibular schwannomas (VS) are benign tumors arising from the Schwann cells of cranial nerve VIII. Historically the prevailing therapy for patients with VS has been microsurgical resection. More recently, stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy have gained acceptance as effective alternatives. Although the side effect profile and rates of tumor control appear to be favorable for SRS, there is a subset of radioresistant tumors that continue to progress despite properly administered radiation treatment. In this review, the authors summarize what is known about the mechanism of radioresistance in VS at the clinical and molecular level. An improved understanding of the radiobiological behavior of VS may help guide appropriate patient selection for SRS and potentially aid in the design of novel therapies to treat radioresistant tumors.
Assuntos
Neuroma Acústico/radioterapia , Neuroma Acústico/cirurgia , Tolerância a Radiação/fisiologia , Radiobiologia , Fracionamento da Dose de Radiação , Relação Dose-Resposta à Radiação , Genes cdc/fisiologia , Genes p53/genética , Genes p53/fisiologia , Humanos , Estudos Longitudinais , Modelos Biológicos , Neurofibromatose 2/radioterapia , Neurofibromatose 2/cirurgia , Neuroma Acústico/genética , Doses de Radiação , Tolerância a Radiação/genética , Radiocirurgia , Dosagem Radioterapêutica , Resultado do Tratamento , Nervo Vestibulococlear/efeitos da radiação , Nervo Vestibulococlear/cirurgiaRESUMO
BACKGROUND: The Manchester criteria for neurofibromatosis type 2 (NF2) include a range of tumors, and gliomas were incorporated in the original description. The gliomas are now widely accepted to be predominantly spinal cord ependymomas. OBJECTIVE: To determine whether these gliomas include any cases of malignant glioma (WHO grade III and IV) through a database review. METHODS: The prospective database consists of 1253 patients with NF2. 1009 are known to be alive at last follow-up. RESULTS: There was a single case of glioblastoma multiforme (GBM; World Health Organization grade IV) in the series and no WHO grade III gliomas. The GBM was in a patient who had previously undergone stereotactic radiosurgery for a vestibular schwannoma. CONCLUSION: High-grade gliomas are not a feature of NF2 in the unirradiated patient and should be excluded from the diagnostic criteria.
Assuntos
Glioma/etiologia , Neurofibromatose 2/complicações , Adulto , Feminino , Glioma/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Neurofibromatose 2/radioterapia , Estudos Prospectivos , Radiocirurgia/efeitos adversos , Adulto JovemRESUMO
OBJECTIVE Neurofibromatosis Type 2 (NF2) is a tumor syndrome characterized by an autosomal dominant pattern of inheritance. The hallmark of NF2 is the development of bilateral vestibular schwannomas (VSs), generally by 30 years of age. One of the first-line treatment options for small to medium-large VSs is radiosurgery. Although radiosurgery shows excellent results in sporadic VS, its use in NF2-related VS is still a topic of dispute. The aim of this study was to evaluate long-term tumor control, hearing preservation rates, and factors influencing outcome of optimally dosed, contemporary Gamma Knife radiosurgery (GKRS) for growing VSs in patients with NF2 and compare the findings to data obtained in patients with sporadic VS also treated by means of GKRS. METHODS The authors performed a retrospective analysis of 47 growing VSs in 34 NF2 patients who underwent GKRS treatment performed with either the Model C or Perfexion Leksell Gamma Knife, with a median margin dose of 11 Gy. Actuarial tumor control rates were estimated using the Kaplan-Meier method. For patient- and treatment-related factors, a Cox proportional hazards model was used to identify predictors of outcome. Trigeminal, facial, and vestibulocochlear nerve function were assessed before and after treatment. NF2-related VS patients were matched 1:1 with sporadic VS patients who were treated in the same institute, and the same indications for treatment, definitions, and dosimetry were used in order to compare outcomes. RESULTS Actuarial tumor control rates in NF2 patients after 1, 3, 5, and 8 years were 98%, 89%, 87%, and 87%, respectively. Phenotype and tumor volume had significant hazard rates of 0.086 and 22.99, respectively, showing that Feiling-Gardner phenotype and a tumor volume not exceeding 6 cm3 both were associated with significantly better outcome. Actuarial rates of serviceable hearing preservation after 1, 3, 5, and 7 years were 95%, 82%, 59%, and 33%, respectively. None of the patients experienced worsening of trigeminal nerve function. Facial nerve function worsened in 1 patient (2.5%). No significant differences in tumor control, hearing preservation, or complications were found in comparing the results of GKRS for NF2-related VS versus GKRS for sporadic VS. CONCLUSIONS With modern GKRS, the use of low margin doses for treating growing VSs in patients with NF2 demonstrates good long-term tumor control rates. Feiling-Gardner phenotype and tumor volume smaller than 6 cm3 seem to be independently associated with prolonged progression-free survival, highlighting the clinical importance of phenotype assessment before GKRS treatment. In addition, no significant differences in tumor control rates or complications were found in the matched-control cohort analysis comparing GKRS for VS in patients with NF2 and GKRS for sporadic VS. These results show that GKRS is a valid treatment option for NF2-related VS, in addition to being a good option for sporadic VS, particularly in patients with the Feiling-Gardner phenotype and/or tumors that are small to medium in size. Larger tumors in patients with the Wishart phenotype appear to respond poorly to radiosurgery, and other treatment modalities should therefore be considered in such cases.
Assuntos
Neurofibromatose 2/radioterapia , Neuroma Acústico/radioterapia , Radiocirurgia , Adolescente , Adulto , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Neurofibromatose 2/diagnóstico por imagem , Neurofibromatose 2/fisiopatologia , Neuroma Acústico/diagnóstico por imagem , Neuroma Acústico/fisiopatologia , Estudos Prospectivos , Dosagem Radioterapêutica , Estudos Retrospectivos , Resultado do Tratamento , Carga Tumoral , Adulto JovemRESUMO
PURPOSE: To study the natural history, clinical and radiological characteristics of primary paediatric optic nerve sheath meningioma (PPONSM). METHODS: Retrospective study of eight paediatric patients who were treated between 1994 and 2016 at the University Hospital Zurich, Switzerland and the Royal Adelaide Hospital, Australia. Clinical records and imaging studies were reviewed. RESULTS: The mean age at presentation was 11 years (range: 6-17 years). There were six female patients and two male patients. 2/8 patients had associated neurofibromatosis type 2. Patients were followed up for 71-297 months (mean 156±70 months). 6/8 patients were observed through the course of their disease and 2/8 patients were treated with radiotherapy. 2/8 patients who were observed had minimal change in vision and did not experience tumour growth after long-term follow-up. CONCLUSIONS: This is the largest PPONSM case series with long-term data on patients treated conservatively. We highlight that a small subset of these tumours are indolent and can be managed using observation alone.
Assuntos
Imageamento por Ressonância Magnética , Meningioma/diagnóstico por imagem , Neurofibromatose 2/diagnóstico por imagem , Neoplasias do Nervo Óptico/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Adolescente , Criança , Feminino , Seguimentos , Humanos , Masculino , Meningioma/patologia , Meningioma/radioterapia , Neurofibromatose 2/patologia , Neurofibromatose 2/radioterapia , Neoplasias do Nervo Óptico/patologia , Neoplasias do Nervo Óptico/radioterapia , Estudos Retrospectivos , Acuidade Visual , Campos VisuaisRESUMO
BACKGROUND: Resection of a vestibular schwannoma may result in facial paralysis and hearing loss on the side of the tumor. We evaluated clinical, audiologic, and intraoperative events and radiologic parameters in a case of contralateral side sensorineural hearing loss. We also performed a literature search using PubMed. CASE DESCRIPTION: A 25-year-old woman with neurofibromatosis 2 developed contralateral side sensorineural hearing loss immediately after resection of vestibular schwannoma. The patient regained partial hearing with a short course (2 months) of steroid therapy over 6 months. CONCLUSIONS: Literature search yielded 20 cases. We evaluated possible etiology, pattern, extent, recovery, and final outcome in these patients with management options. Several etiologies have been proposed, including development of endolymphatic hydrops, vascular phenomenon, mechanical injury, barotrauma, and autoimmune cochleolabyrinthitis. Sudden release of cerebrospinal fluid seemed to be the most likely explanation in the present case. There is no way to predict this complication beforehand. Operating in supine position, slow release of cerebrospinal fluid, irrigation of the operating field, maintenance of normotension, and judicious use of the drill may help in prevention. A short course of corticosteroids and vasodilators helped in spontaneous recovery in most of the cases.
Assuntos
Perda Auditiva Neurossensorial/etiologia , Neurofibromatose 2/complicações , Neuroma Acústico/complicações , Neuroma Acústico/cirurgia , Complicações Pós-Operatórias , Adulto , Feminino , Lateralidade Funcional , Perda Auditiva Neurossensorial/tratamento farmacológico , Humanos , Neurofibromatose 2/diagnóstico por imagem , Neurofibromatose 2/radioterapia , Neurofibromatose 2/cirurgia , Neuroma Acústico/diagnóstico por imagem , Neuroma Acústico/radioterapia , Complicações Pós-Operatórias/tratamento farmacológicoRESUMO
This article presents the current diagnostic and treatment options for the hereditary disease neurofibromatosis type II, reviews clinical presentation and diagnosis, highlights indications for and methods of clinical and genetic screening, discusses treatment approaches for surgery and stereotactic radiation, and summarizes potential future therapeutic avenues.
Assuntos
Neurofibromatose 2/diagnóstico , Neurofibromatose 2/terapia , Descompressão Cirúrgica , Testes Genéticos , Perda Auditiva/reabilitação , Humanos , Imageamento por Ressonância Magnética , Neurofibromatose 2/genética , Neurofibromatose 2/fisiopatologia , Neurofibromatose 2/radioterapiaRESUMO
Neurofibromatosis type 2 (NF2) is a dominantly inherited genetic condition. Bilateral vestibular schwannoma, which are benign tumors, composed of neoplastic Schwann cells that arise from the eighth cranial nerve, are the hallmark of NF2. Standard approaches for treatment of growing vestibular schwannoma include observation, surgical removal and radiation therapy. Molecular targeted therapies also present great prosperity in recent years. In this review, we summarize the latest progresses on the treatment of NF2-associated vestibular schwannoma.
Assuntos
Neurofibromatose 2/terapia , Neuroma Acústico/terapia , Humanos , Terapia de Alvo Molecular , Neurofibromatose 2/radioterapia , Neurofibromatose 2/cirurgia , Neuroma Acústico/radioterapia , Neuroma Acústico/cirurgiaRESUMO
PURPOSE: Analysis of local tumor control and functional outcome following conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. PATIENTS AND METHODS: From 11/1989 to 9/1999 51 patients with acoustic neuromas have been treated by FSRT. Mean total dose was 57.6 +/- 2.5 Gy. Forty-two patients have been followed for at least 12 months and were subject of an outcome analysis. Mean follow-up was 42 months. We analyzed local control, hearing preservation, and facial and trigeminal nerve functional preservation. We evaluated influences of tumor size, age, and association with neurofibromatosis Type 2 (NF2) on outcome and treatment related toxicity. RESULTS: Actuarial 2- and 5-year tumor control rates were 100% and 97.7%, respectively. Actuarial useful hearing preservation rate was 85% at 2 and 5 years. New hearing loss was diagnosed in 4 NF2 patients. Pretreatment normal facial nerve function was preserved in all cases. Two cases of new or impaired trigeminal nerve dysesthesia required medication. No other cranial nerve deficit was observed. In Patients without NF2 tumor size or age had no influence on tumor control and cranial nerve toxicity. Diagnosis of NF2 was associated with higher risk of hearing impairment (p = 0.0002), the hearing preservation rate in this subgroup was 60%. CONCLUSION: FSRT has been shown to be an effective means of local tumor control. Excellent hearing preservation rates and 5th and 7th nerve functional preservation rates were achieved. The results support the conclusion that FSRT can be recommended to patients with acoustic neuromas where special attention has to be taken to preserve useful hearing and normal cranial nerve function. For NF2 patients, FSRT may be the treatment of choice with superior functional outcome compared to treatment alternatives.
Assuntos
Neuroma Acústico/cirurgia , Radiocirurgia/métodos , Análise Atuarial , Adulto , Idoso , Idoso de 80 Anos ou mais , Paralisia de Bell/etiologia , Surdez/etiologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Neurofibromatose 2/radioterapia , Neuroma Acústico/patologia , Dosagem Radioterapêutica , Resultado do Tratamento , Doenças do Nervo Trigêmeo/etiologiaRESUMO
OBJECTIVE: Review the useful hearing preservation and tumor control outcomes of microsurgery (MS), stereotactic radiation (SR), conservative management (CM), and chemotherapy (ChT) for Neurofibromatosis type 2 vestibular schwannomas. DATA SOURCES: Ovid MEDLINE was used to conduct a thorough search of English-language publications dating from 1948 to February 2013. STUDY SELECTION: Patients must have had useful hearing at diagnosis and treated with one of the 4 treatments as their primary therapy. All sporadic vestibular schwannoma cases were excluded. DATA EXTRACTION: A total of 19 articles were reviewed. Hearing preservation was defined as unchanged or improved useful hearing. Tumor control was defined as no change in size or tumor regression for SR, CM, and ChT-treated cases, and as no recurrence for MS treated cases. CONCLUSION: Microsurgery seems to have the worse overall results, while SR has very good tumor control with poor useful hearing preservation. If a patient qualifies for CM, he is likely to show the most satisfactory results with the least treatment available. A close follow-up on ChT clinical trials and possible side-effects is warranted as preliminary short-term results are quite favorable. Additional long-term studies are required for a better understanding of this disease.
Assuntos
Neurofibromatose 2/terapia , Neuroma Acústico/terapia , Humanos , Neurofibromatose 2/tratamento farmacológico , Neurofibromatose 2/radioterapia , Neurofibromatose 2/cirurgia , Neuroma Acústico/tratamento farmacológico , Neuroma Acústico/radioterapia , Neuroma Acústico/cirurgia , Resultado do TratamentoRESUMO
OBJECTIVES: Vestibular schwannomas are the hallmark of neurofibromatosis type two. They are difficult to treat, due to their bilateral presentation and the quest for hearing preservation. Our report describes a new treatment approach in this clinical scenario. CASE REPORT: We report two cases which confirm that bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, causes regression of vestibular schwannomas in patients with a previous history of gamma knife radiosurgery or failed treatment with another form of vascular endothelial growth factor targeted therapy. CONCLUSION: In 2009, Plotkin et al. reported the volumetric response of vestibular schwannomas to bevacizumab treatment, both in untreated patients and in patients previously treated with erlotinib, an epidermal growth factor receptor inhibitor. The presented cases support the use of bevacizumab to treat vestibular schwannomas. Given the extremely slow growth of these tumours, we note the rapidity of volume reduction following bevacizumab therapy.
Assuntos
Inibidores da Angiogênese/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Perda Auditiva Unilateral/prevenção & controle , Neurofibromatose 2/tratamento farmacológico , Neuroma Acústico/tratamento farmacológico , Adulto , Inibidores da Angiogênese/administração & dosagem , Anticorpos Monoclonais Humanizados/administração & dosagem , Bevacizumab , Meios de Contraste , Feminino , Gadolínio , Perda Auditiva Unilateral/etiologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Neurofibromatose 2/complicações , Neurofibromatose 2/radioterapia , Neurofibromatose 2/cirurgia , Neuroma Acústico/etiologia , Neuroma Acústico/radioterapia , Neuroma Acústico/cirurgia , Radiocirurgia/instrumentação , Indução de Remissão/métodos , Resultado do Tratamento , Fatores de Crescimento do Endotélio VascularRESUMO
OBJECTIVE: To investigate the results of cochlear implantation in patients with neurofibromatosis Type 2 (NF2) who have previously been treated with radiation therapy to the vestibular schwannoma (VS) in their only hearing ear. STUDY DESIGN: A retrospective review of the Melbourne Cochlear implant database was undertaken to identify patients with NF2 undergoing cochlear implantation in whom previous radiation therapy had been performed to control their VS (ipsilateral tumor). Three patients were identified. A case note review was undertaken and data collected on preoperative and postoperative speech perception testing. SETTING: Melbourne Cochlear implant center. RESULTS: All 3 patients were daily cochlear implant users. There was improvement in speech perception scores in 2 cases, with the 3rd case unable, for unrelated medical reasons, to complete postoperative testing. Subjectively, the third patient reported a dramatic improvement in communication and is a daily user of his implant. CONCLUSION: Cochlear implantation results in improved hearing in a select group of NF2 patients who have undergone radiation treatment to control their VS.
Assuntos
Implante Coclear , Neurofibromatose 2/complicações , Neurofibromatose 2/radioterapia , Adulto , Idoso de 80 Anos ou mais , Comunicação , Neoplasias da Orelha/complicações , Neoplasias da Orelha/radioterapia , Feminino , Perda Auditiva/etiologia , Perda Auditiva/terapia , Humanos , Leitura Labial , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neuroma Acústico/complicações , Neuroma Acústico/radioterapia , Complicações Pós-Operatórias/terapia , Radiocirurgia , Recuperação de Função Fisiológica , Estudos Retrospectivos , Percepção da Fala , Resultado do TratamentoRESUMO
OBJECT: Reports on spinal cord ependymoma in children are rare. The aim of this study was to evaluate the clinical spectrum, treatment, and outcome of children with primary ependymoma of the spinal cord who were registered in the database of the pediatric German brain tumor studies Hirntumor (HIT) '91 and HIT 2000. METHODS: Between 1991 and 2007, 29 patients (12 male and 17 female, median age at diagnosis 13.6 years) with primary spinal cord ependymoma (myxopapillary ependymoma WHO Grade I, II, and III tumors in 6, 17, and 6 patients, respectively) were identified. Four patients had neurofibromatosis Type 2. RESULTS: With a median follow-up of 4.2 years (range 0.48-15 years), 28 patients (96.6%) were alive. Seven patients (24.1%) developed progressive disease or relapse, 2 after gross-total resection (GTR) and 5 after incomplete resection or biopsy. One patient with anaplastic ependymoma (WHO Grade III) died 65 months after diagnosis of disease progression. Primary adjuvant treatment (radiotherapy, chemotherapy, or both) was used in 8 (50%) of 16 patients following GTR and in 9 (82%) of 11 patients who underwent less than a GTR. Three additional patients were treated adjuvantly following progression. Estimated progression-free survival and overall survival rates at 5 years were 72.3% (95% CI 50%-86%) and 100%, respectively. Progression-free survival at 5 years is 84.4% (95% CI 50%-96%) for patients following GTR compared with 57.1% (95% CI 25%-69%) for patients who achieved a less than GTR (p = 0.088, log-rank test). A high relapse incidence (4 of 6) was observed among patients with myxopapillary ependymoma. CONCLUSIONS: Gross-total resection is the mainstay of treatment for patients with primary spinal cord ependymoma and may be achieved in about 50% of the patients using modern surgical techniques. Primary adjuvant treatment was commonly used in children with spinal cord ependymoma irrespective of the extent of resection or tumor grade. The impact of adjuvant treatment on progression-free and overall survival has to be investigated in a prospective trial.
Assuntos
Ependimoma/cirurgia , Neoplasias da Medula Espinal/cirurgia , Adolescente , Áustria , Biópsia , Quimioterapia Adjuvante , Criança , Terapia Combinada , Avaliação da Deficiência , Progressão da Doença , Ependimoma/diagnóstico , Ependimoma/tratamento farmacológico , Ependimoma/patologia , Ependimoma/radioterapia , Feminino , Seguimentos , Alemanha , Humanos , Masculino , Neurofibromatose 2/diagnóstico , Neurofibromatose 2/tratamento farmacológico , Neurofibromatose 2/patologia , Neurofibromatose 2/radioterapia , Neurofibromatose 2/cirurgia , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/mortalidade , Estudos Prospectivos , Radioterapia Adjuvante , Sistema de Registros , Neoplasias da Medula Espinal/diagnóstico , Neoplasias da Medula Espinal/tratamento farmacológico , Neoplasias da Medula Espinal/patologia , Neoplasias da Medula Espinal/radioterapia , Taxa de SobrevidaRESUMO
Neurofibromatosis 2 (NF2) results in multiple central nervous system tumours. In this case report, the patient has one vestibular schwannoma, one trigeminal schwannoma and two meningiomas developed before the age of 30. Aiming to treat three targets at one fraction with minimal interaction and overlapping doses to normal tissue, the sophisticated equipment of tomotherapy was utilised for frameless stereotaxy; tomotherapy delivered intensity-modulated, rotational radiation therapy using a fan-beam delivery. Daily CT scans with the inbuilt CT scanner were also performed as part of the image-guided radiotherapy. The course of fractionated stereotactic radiotherapy consisted of eight fractions given three times per week with an overall treatment time of 17 days. For the meningioma over left parietal vertex, 4.5 Gy per fraction was given at 36 Gy/8 Fr/17 days. For the meningioma over anterior cerebral falx, 4 Gy per fraction was given at 32 Gy/8 Fr/17 days. For the two schwannomas as one target, 5 Gy per fraction was given at 40 Gy/8 Fr/17 days. The acute effect of the treatment was alopecia and mild headache. Subsequent follow-up confirmed clinical improvement. This is the first reported case of clinical experience with tomotherapy in the management of NF2.
Assuntos
Neoplasias Encefálicas/radioterapia , Meningioma/radioterapia , Neurofibromatose 2/radioterapia , Radioterapia de Intensidade Modulada/métodos , Adulto , Neoplasias Encefálicas/diagnóstico , Fracionamento da Dose de Radiação , Feminino , Humanos , Imageamento por Ressonância Magnética , Meningioma/diagnóstico , Neurilemoma/diagnóstico , Neurilemoma/radioterapia , Neurofibromatose 2/diagnóstico , Neuroma Acústico/diagnóstico , Neuroma Acústico/radioterapia , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Doenças do Nervo Trigêmeo/diagnóstico , Doenças do Nervo Trigêmeo/radioterapiaRESUMO
OBJECTIVES: The incidence of malignant peripheral nerve sheath tumor (MPNST) is approximately 0.001%. Those involving intracranial nerves are even more exceptional. Little information is available concerning work up and management. Our objective is: (1) to review all cases of intracranial MPNST described in the literature, (2) to highlight the suspicion of intracranial MPNST, (3) to identify the gross pathology, the histopathology, the immunohistochemistry, (4) to discuss the differential diagnosis, the treatment, the recurrence rate, the follow-up, the incidence of metastasis and the prognosis. METHODS: We reviewed English, Spanish and French literature published from 1950 to date. We used the following Keywords: "malignant peripheral nerve sheath tumor", "cranial nerve", "neurosarcoma", "malignant schwannoma", "neurofibroma", "malignant neurofibroma" and "nerve tumor". We considered cases where MPNST involved an intracranial cranial nerve. The results yielded 20 relevant studies, in which 31 patient's records were transcribed. We also added our case to this series. RESULTS: We identified 32 cases of cranial MPNST including our case. The age ranged from 5 to 75 years old with most patients being in the 5th and 6th decade. Male to female ratio is 2.5:1. Most cases are developed sporadically (50%), 31% arise from a malignant transformation of schwannoma and 19% from a neurofibroma. Imaging findings were not specific. The cranial nerve VIII is the most involved (15/32), followed by the Vth (10/32) and the VIIth (5/32). 4 cases had neurofibromatosis type 1 and 2 had neurofibromatosis type 2. MPNST will strongly express protein S-100 and collagen IV-laminin. 13 cases were treated with radiotherapy for tumor recurrence and metastasis. In these cases the survival rate was better than the cases without radiotherapy. Fatal outcome occurred in 66% of patients whereas 19% were reported alive with or without complications. The seven cases reported to have metastasis were entirely to the spine. The mean time of recurrence or metastasis is 12.2 months. CONCLUSION: MPNST of cranial nerves are very rare. In neurofibroma, even though MPNST is mainly associated to type 1, we should keep in mind its association to NF2. Mainstay of treatment is radical resection with adjuvant radiotherapy. Inaccessibility of cranial MPNST may explain the subtotal resection and thus the poor prognosis. Metastasis to the spinal cord is the most frequent one. A close postoperative follow-up is mandatory to eliminate recurrence.